biosimilars

AMCP Annual Meeting highlights specialty pharmaceutical challengesThe CEO of the Academy of Managed Care Pharmacy identifies key challenges and opportunities that will be discussed at the annual meeting.
Assessing the impact of biosimilars on cost, qualityA new report from IMS Institute for Healthcare Informatics finds that biosimilar acceptance will grow and drive change in the healthcare system.
Biosimilar approvals deemed “too slow”While FDA’s approval last week of infliximab-dyyb (Inflectra, Celltrion and Hospira), a biosimilar to Remicade (Janssen Biotech) for rheumatoid arthritis, Chron’s disease and other conditions is positive, FDA’s approval pace for biosimilars is too slow, according to a pharmacy benefit manager (PBM).
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
U.S. physicians start to embrace prescribing of biosimilarsPhysicians are beginning to understand the value of biosimilars, particularly those who are high prescribers of biologics and therefore familiar with biosimilars.
Drug spending rising at slower pacePBM Express Scripts shares findings from its new Drug Trend Report.
The implications in the future of biosimilarsThe FDA is evaluating biosimilar medications for use in the United States. The approval of these medications in the next few years could mean big changes for dermatologists and their psoriasis patients
Another win for biosimilar arthritis drugsIn another win for biosimilar drugs, FDA staff recently decided that Celltrion and Pfizer’s biosimilar (Remsima) to Johnson & Johnson’s Remicade for rheumatoid arthritis was “highly similar” to the branded drug.
LAW: Primer on biosimilar agents: What the pharmacist needs to know
LAW: Primer on biosimilar agents: What the pharmacist needs to knowThe goal of this program is to educate pharmacists and pharmacy technicians about the legal and regulatory pathways for biosimilars approved by the US FDA.
Reimbursement hurdles associated with biosimilarsOptimism exists for biosimilars in the United States, but questions regarding FDA approval and reimbursement remain.